Download Indications Important Safety Information The first and only single

For patients who stand up to their cancer
For health care teams that stand up for their patients
The first and only single agent with a significant overall survival benefit
in advanced liposarcoma and following 2 prior chemotherapies for
metastatic breast cancer1-5
HALAVEN improved median overall
survival in advanced liposarcoma
vs dacarbazine (15.6 months vs 8.4
months) and in mBC vs Treatment of
Physician’s Choice (13.2 months vs
10.6 months) when following 2 prior
mBC therapies4
Indications
Metastatic Breast Cancer
HALAVEN (eribulin mesylate) Injection is indicated for the treatment of patients with metastatic
breast cancer (mBC) who have previously received at least 2 chemotherapeutic regimens for the treatment
of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the
adjuvant or metastatic setting.
Liposarcoma
HALAVEN is indicated for the treatment of patients with unresectable or metastatic liposarcoma who
have received a prior anthracycline-containing regimen.
Important Safety Information
Warnings and Precautions
Neutropenia: Severe neutropenia (ANC <500/mm3) lasting >1 week occurred in 12% of patients with
mBC and liposarcoma or leiomyosarcoma. Febrile neutropenia occurred in 5% of patients with mBC
and 2 patients (0.4%) died from complications. Febrile neutropenia occurred in 0.9% of patients with
liposarcoma or leiomyosarcoma, and fatal neutropenic sepsis occurred in 0.9% of patients. Patients with
mBC with elevated liver enzymes >3 × ULN and bilirubin >1.5 × ULN experienced a higher incidence of
Grade 4 neutropenia and febrile neutropenia than patients with normal levels. Monitor complete blood
cell counts prior to each dose, and increase the frequency of monitoring in patients who develop
Grade 3 or 4 cytopenias. Delay administration and reduce subsequent
doses in patients who experience febrile neutropenia or Grade 4
neutropenia lasting >7 days.
Please see additional Important Safety Information throughout
and accompanying HALAVEN full Prescribing Information.
HALAVEN—the
first agent in the
halichondrin class6
Preclinical studies have demonstrated the ability of HALAVEN® to
Induce tumor cell death
With its distinct binding profile, HALAVEN causes irreversible mitotic
blockage resulting in apoptosis, leading to the destruction of many
tumor cells4,7-9
HALAVEN binds with high affinity to the growing plus
ends of microtubules.10
Microtubule growth occurs primarily at these plus ends7
HALAVEN sequesters tubulin into nonproductive aggregates,
preventing participation in microtubule assembly.4,9
Microtubules are a key part of the cell-division process,
allowing tumor growth11
HALAVEN inhibits microtubule growth and prevents normal
mitotic spindle formation.4,7
Disruption of microtubule function results in mitotic
blockage, leading to tumor cell death by apoptosis7
HALAVEN induces apoptosis and
may impact the residual tumor cells4,12
Important Safety Information (continued)
Peripheral Neuropathy: Grade 3 peripheral neuropathy occurred in 8% of patients with mBC
(Grade 4=0.4%) and 22% developed a new or worsening neuropathy that had not recovered
within a median follow-up duration of 269 days (range 25-662 days). Neuropathy lasting
>1 year occurred in 5% of patients with mBC.
2
Please see additional Important Safety Information throughout
and accompanying HALAVEN full Prescribing Information.
MECHANISM OF ACTION
Alter the tumor microenvironment*
By promoting the epithelial phenotype, HALAVEN reduces the migration and
invasive capacity of tumor cells4,12,13
HALAVEN induces vascular remodeling, increasing
oxygen flow to the tumor.4,13
Abnormal vasculature causes irregular blood flow throughout
the tumor, resulting in hypoxic regions14
HALAVEN reduces the hypoxic conditions associated
with an abnormal tumor microenvironment.4,13
Hypoxic conditions lead to phenotypic changes that cause
increased migration and invasive capacity of the tumor cells14,15
Mesenchymal
cell
HALAVEN opposes the mesenchymal phenotype and
promotes the epithelial phenotype.4,12
Epithelial
cell
The mesenchymal phenotype correlates with increased
migration and invasiveness of tumor cells12
HALAVEN makes the residual tumor cells into
ones that are less prone to migrate and invade4
Preclinical evidence does not imply clinical efficacy.
*Based on preclinical studies of human breast cancer models (in vitro/in vivo).
Important Safety Information (continued)
Grade 3 peripheral neuropathy occurred in 3.1% of patients with liposarcoma and
leiomyosarcoma receiving HALAVEN and neuropathy lasting more than 60 days occurred
in 58% (38/65) of patients who had neuropathy at the last treatment visit. Patients should be
monitored for signs of peripheral motor and sensory neuropathy. Withhold HALAVEN in
patients who experience Grade 3 or 4 peripheral neuropathy until resolution to Grade 2 or less.
3
The treatment landscape in mBC is changing
Although mBC treatment can potentially extend to 6 lines and beyond,
not all patients will be alive to benefit from subsequent lines of therapy16
ESTIMATED REDUCTION IN PATIENTS ALIVE BY THE END OF EACH LINE OF THERAPY17
METASTATIC
BREAST CANCER
First line
Second line
Third line
Fourth line
mBC=metastatic breast cancer.
It’s important to choose an option following 2 prior mBC therapies
that gives more patients an opportunity for an OS benefit17
OS=overall survival.
Important Safety Information (continued)
Embryo-Fetal Toxicity: HALAVEN can cause fetal harm when administered to a pregnant
woman. Advise females of reproductive potential to use effective contraception during
treatment with HALAVEN and for at least 2 weeks following the final dose. Advise males
with female partners of reproductive potential to use effective contraception during
treatment with HALAVEN and for 3.5 months following the final dose.
Please see additional Important Safety Information throughout
and accompanying HALAVEN full Prescribing Information.
5
ERIBULIN (HALAVEN) IS
LISTED AS A PREFERRED
SINGLE AGENT IN THE
NCCN CLINICAL PRACTICE
GUIDELINES IN ONCOLOGY
(NCCN GUIDELINES®)18
The first and only single
agent that significantly extended
overall survival following
2 prior mBC therapies1-3
UPDATED OS ANALYSIS (UNPLANNED):
MEDIAN OS, MONTHS (95% CI)1,4,a
PROPORTION OF PATIENTS ALIVE
1.0
0.9
HALAVEN
0.8
(n=508)
0.7
13.2
0.6
0.5
months
Treatment of
Physician’s Choice
(n=254)
0.4
0.3
(12.1, 14.4)
Deaths=386
10.6
months
0.2
(9.2, 12.0)
Deaths=203
0.1
0.0
0
6
12
18
24
30
36
11
5
0
0
TIME (MONTHS)
Number of
patients
at risk
508
254
406
178
274
106
142
61
54
26
HALAVEN
TPC
Results from an updated, unplanned survival analysis of the Phase III, randomized (2:1), open-label, multicenter, multinational Eisai Metastatic Breast Cancer Study
Assessing Physician’s Choice versus E7389 (Eribulin) (EMBRACE) trial of HALAVEN versus Treatment of Physician’s Choice (TPC) (Control arm) in patients with mBC
(N=762), conducted when 77% of events (deaths) had been observed.1,4
NCCN®=National Comprehensive Cancer Network®; CI=confidence interval.
a
Conducted in the intent-to-treat population.
Patients in the HALAVEN arm had a
19% reduction in relative risk of death vs control group4,19
Results of the updated analysis were consistent with the primary analysis, which was
conducted when ~50% of events (deaths) had been observed. HALAVEN demonstrated
median overall survival of 13.1 months (95% CI: 11.8, 14.3) vs 10.6 months with the
TPC arm (95% CI: 9.3, 12.5), hazard ratio=0.81 (95% CI: 0.66, 0.99) (P=0.041)1,4
6
Please see additional Important Safety Information throughout
and accompanying HALAVEN full Prescribing Information.
Evaluated against real-world, single-agent
treatment options used by physicians
THE PHASE III EMBRACE TRIAL: RANDOMIZED, OPEN-LABEL, MULTICENTER, MULTINATIONAL1,4
Patients with metastatic
breast cancer (N=762)
• ≥2 chemotherapeutic
regimens for
metastatic disease
RANDOMIZATION (2:1)b
• Prior anthracyclineand taxane-based
chemotherapy, unless
contraindicated
• Progression within 6 months
of last chemotherapeutic regimen
HALAVEN
(n=508)
1.4 mg/m2 IV for
2 to 5 minutes
Days 1 and 8
(21-day cycle)
TPC
(Control arm, n=254)c
Any single-agent
therapy, selected prior
to randomization
PRIMARY
ENDPOINT:
OS
IV=intravenous.
Randomization was stratified by geographic region, human epidermal growth factor receptor 2 (HER2/neu) status, and prior capecitabine exposure.
c
Therapies included in the TPC arm were determined prior to randomization to eliminate bias and had to be approved for the treatment of cancer, administered
according to local practice, and available at time of study.
b
The FDA recognizes overall survival as the most reliable
and preferred clinical endpoint in cancer trials20
Important Safety Information (continued)
QT Prolongation: Monitor for prolonged QT intervals in patients with congestive heart failure,
bradyarrhythmias, drugs known to prolong the QT interval, and electrolyte abnormalities.
Correct hypokalemia or hypomagnesemia prior to initiating HALAVEN and monitor these
electrolytes periodically during therapy. Avoid in patients with congenital long QT syndrome.
7
Patients in the Treatment of Physician's Choice
(TPC) arm primarily received chemotherapy
THERAPIES IN THE TPC ARM4
26%
Vinorelbine
Gemcitabine
18%
Capecitabine
18%
Taxanesa
16%
Other chemotherapyb
10%
Anthracyclines
Hormone therapy
9%
3%
Included paclitaxel, docetaxel, nab-paclitaxel, and ixabepilone.1
Included cisplatin, carboplatin, cyclophosphamide, etoposide, mitomycin, fluorouracil, and methotrexate.1
a
b
97% of patients in the TPC arm received chemotherapy4
8
Please see Important Safety Information throughout
and accompanying HALAVEN full Prescribing Information.
Studied in patients regardless of receptor status
BASELINE PATIENT CHARACTERISTICS21
HALAVEN
TPC
(n=508)
(n=254)
55 years (28 to 85)
56 years (27 to 81)
0
43%
41%
1
48%
50%
2
8%
9%
Positive
18%
17%
Negative
81%
83%
Unknown
1%
0%
Positive
70%
70%
Negative
30%
30%
Unknown
<1%
0%
Positive
56%
55%
Negative
44%
45%
Unknown
<1%
0%
HER2/neu-, ER-, PR-
18%
21%
Liver
58%
63%
Lung
39%
37%
Bone
60%
62%
2
34%
32%
3
29%
30%
4
14%
15%
2
43%
36%
3
32%
33%
4
18%
22%
SELECTED PATIENT FACTORS
Median age (range)
ECOG PS
HER2/neu status
ER status
PR status
Triple negative
Sites of involvement
Metastatic sites
Number of prior mBC chemotherapy regimens
ECOG PS=Eastern Cooperative Oncology Group performance status; ER=estrogen receptor; PR=progesterone receptor.
Evaluated in patients with pre-existing peripheral neuropathy: at baseline, 17%
of enrolled patients had Grade 1 peripheral neuropathy and 3% had Grade 24
More patients (43%) received HALAVEN following
2 prior mBC therapies than in later settings21
9
Choose HALAVEN® when your goal is extending
life following 2 prior mBC therapies
A treatment option for
patients with mBC4
Who are still active
(ECOG PS 0 or 1)4
Who are ready for
chemotherapy after
2 prior chemotherapy
regimens for mBC, which
should have included an
anthracycline and a taxane
in the adjuvant or
metastatic setting4
Regardless of
receptor status4,21
• ER/PR +/• HER2 +/• Triple negative
A growing body of real-world experience
HALAVEN has been prescribed to approximately 40,000 patients
with mBC in the United States21
Important Safety Information (continued)
Adverse Reactions
In patients with mBC receiving HALAVEN, the most common adverse reactions (≥25%)
were neutropenia (82%), anemia (58%), asthenia/fatigue (54%), alopecia (45%), peripheral
neuropathy (35%), nausea (35%), and constipation (25%). Febrile neutropenia (4%) and
neutropenia (2%) were the most common serious adverse reactions. The most common
adverse reaction resulting in discontinuation was peripheral neuropathy (5%).
10
Please see additional Important Safety Information throughout
and accompanying HALAVEN full Prescribing Information.
Safety profile demonstrated in the Phase III
EMBRACE trial
ADVERSE REACTIONS4,a
HALAVEN
TPC
(n=503)
(n=247)
INCIDENCE ≥10% BY GRADE All≥3
All≥3
Neutropenia
82%
57%
53%
23%
Anemia
58%
2%
55%
4%
Peripheral neuropathyc
35%
8%
16%
2%
Headache
19%
<1%
12%
<1%
Asthenia/Fatigue
54%
10%
40%
11%
Pyrexia
21%
<1%
13%
<1%
9%
1%
10%
2%
Nausea
35%
1%
28%
3%
Constipation
25%
1%
21%
1%
Vomiting
18%
1%
18%
1%
Diarrhea
18%
0%
18%
0%
Arthralgia/Myalgia
22%
<1%
12%
1%
Back pain
16%
1%
7%
2%
Bone pain
12%
2%
9%
2%
Pain in extremity
11%
1%
10%
1%
Metabolism and
nutrition disorders
Decreased weight
21%
1%
14%
<1%
Anorexia
20%
1%
13%
1%
Respiratory, thoracic,
and mediastinal disorders
Dyspnea
16%
4%
13%
4%
Cough
14%
0%
9%
0%
Skin and subcutaneous
tissue disorders
Alopecia
45%
NAd
10%
NAd
Infections
Urinary tract infection
10%
1%
5%
0%
Blood and lymphatic
system disordersb
Nervous system disorders
General disorders
Mucosal inflammation
Gastrointestinal disorders
Musculoskeletal and
connective tissue disorders
Adverse reactions were graded per National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.4
Based upon laboratory data.4
c
Includes peripheral neuropathy, peripheral sensorimotor neuropathy, peripheral motor neuropathy (in the HALAVEN arm: all Grades=4%, Grade 3=2%), polyneuropathy,
peripheral sensory neuropathy, and paresthesia.4
d
Not applicable; grading system does not specify greater than Grade 2 for alopecia. Rate of alopecia in the HALAVEN arm: Grade 1=26%, Grade 2=17%. Rate of
alopecia in the TPC arm: Grade 1=5%, Grade 2=5%.4,21
a
b
The median duration of exposure was 118 days in the HALAVEN arm
and 63 days in the TPC arm4
11
Increasing overall survival has been challenging
in patients with soft tissue sarcomas22
An expected median
survival of 8 to 13 months
is estimated from the start
of a first-line anthracycline
in advanced soft
tissue sarcoma22
In patients with liposarcoma
for whom surgical resection
is not an option, the mortality
rate is high across subtypes
(well and dedifferentiated,
myxoid/round cell,
and pleomorphic)22
ADVANCED
LIPOSARCOMA
Both dedifferentiated and
pleomorphic subtypes have
shown low responsiveness
to typical regimens22
There is an opportunity to extend overall survival
for patients with advanced liposarcoma4,5
Important Safety Information (continued)
Adverse Reactions (continued)
In patients with liposarcoma and leiomyosarcoma receiving HALAVEN, the most common
adverse reactions (≥25%) reported in patients receiving HALAVEN were fatigue (62%),
nausea (41%), alopecia (35%), constipation (32%), peripheral neuropathy (29%), abdominal
pain (29%), and pyrexia (28%). The most common (≥5%) Grade 3-4 laboratory abnormalities
reported in patients receiving HALAVEN were neutropenia (32%), hypokalemia (5.4%), and
hypocalcemia (5%). Neutropenia (4.9%) and pyrexia (4.5%) were the most common serious
adverse reactions. The most common adverse reactions resulting in discontinuation were
fatigue and thrombocytopenia (0.9% each).
Please see additional Important Safety Information throughout
and accompanying HALAVEN full Prescribing Information.
13
ERIBULIN (HALAVEN)
IS LISTED AS A SINGLE
AGENT FOR PALLIATIVE
THERAPY IN THE
NCCN CLINICAL
PRACTICE GUIDELINES
IN ONCOLOGY
(NCCN GUIDELINES®)23
The first and only single agent to
show a significant survival advantage
in a Phase III study of patients with
advanced liposarcoma5
OVERALL SURVIVAL ANALYSIS (LIPOSARCOMA STRATUM):
MEDIAN OS, MONTHS (95% CI)4
1.0
SURVIVAL PROBABILITY
0.8
HALAVEN
(n=71)
15.6
0.6
months
0.4
(10.2, 18.6)
Deaths=52
Dacarbazine
(n=72)
8.4
0.2
months
(5.2, 10.1)
Deaths=63
0.0
0
3
6
9
12
15
18
21
24
27
30
33
36
39
42
45
7
2
4
0
2
0
0
0
0
0
0 HALAVEN
0 Dacarbazine
TIME (MONTHS)
Number of
patients
at risk
71
72
63
59
51
42
43
33
39
22
34
17
30
12
20
11
15
6
12
3
The efficacy and safety of HALAVEN were evaluated in an open-label, randomized (1:1), multicenter, active-controlled trial. Eligible patients were required to have
unresectable, locally advanced, or metastatic liposarcoma or leiomyosarcoma, at least 2 prior systemic chemotherapies (one of which must have included an
anthracycline), and disease progression within 6 months of the most recent chemotherapy regimen. Patients were randomized to HALAVEN 1.4 mg/m2 administered
intravenously on Days 1 and 8 of a 21-day cycle or to dacarbazine at a dose of 850 mg/m2, 1,000 mg/m2, or 1,200 mg/m2 administered intravenously every 21 days
(dacarbazine dose was selected by the investigator prior to randomization). Treatment continued until disease progression or unacceptable toxicity. Randomization
was stratified by histology (liposarcoma or leiomyosarcoma), number of prior therapies (2 vs >2), and geographic region. The most common (>40%) prior systemic
chemotherapies were doxorubicin (90%), ifosfamide (62%), gemcitabine (59%), trabectedin (50%), and docetaxel (48%).4
NCCN®=National Comprehensive Cancer Network®; OS=overall survival; CI=confidence interval.
Patients in the HALAVEN arm with liposarcoma had a
49% reduction in relative risk of death vs control group4,19
14
Please see additional Important Safety Information throughout
and accompanying HALAVEN full Prescribing Information.
Treatment effects of HALAVEN® were demonstrated
in patients with advanced liposarcoma based on
the preplanned, exploratory subgroup analysis of
OS and PFS4
MEDIAN OS FOR HALAVEN AND DACARBAZINE:
LIPOSARCOMA STRATUM AND ALL PATIENTS4,a,b
18
MEDIAN OS, MONTHS (95% CI)
16
15.6
(10.2, 18.6)
n=71
13.5
(11.1, 16.5)
n=225
14
12
10
8.4
11.3
(9.5, 12.6)
n=221
(5.2, 10.1)
n=72
8
6
4
HALAVEN
Dacarbazine
2
0
LIPOSARCOMA
HR=0.51 (95% CI: 0.35, 0.75)
ALL PATIENTSb
HR=0.75 (95% CI: 0.61, 0.94), P=0.011
PFS=progression-free survival; HR=hazard ratio.
Efficacy data from 1 study site enrolling 6 patients were excluded.
b
All patients=liposarcoma and leiomyosarcoma.
a
There was no evidence of efficacy of HALAVEN in patients with advanced or metastatic
leiomyosarcoma in this trial4
Secondary endpoint: PFS4
Median PFS in the liposarcoma stratum was 2.9 months (95% CI: 2.6, 4.8) for patients
receiving HALAVEN vs 1.7 months (95% CI: 1.4, 2.6) for patients receiving dacarbazine,
HR=0.52 (95% CI: 0.35, 0.78)
Median PFS in all patients was 2.6 months (95% CI: 2.0, 2.8) for patients receiving
HALAVEN vs 2.6 months (95% CI: 1.7, 2.7) for patients receiving dacarbazine, HR=0.86
(95% CI: 0.69, 1.06)
Important Safety Information (continued)
Use in Specific Populations
Lactation: Because of the potential for serious adverse reactions in breastfed infants from
eribulin mesylate, advise women not to breastfeed during
treatment with HALAVEN and for 2 weeks after the final dose.
15
Evaluated against dacarbazine
A Phase III, open-label, randomized, multicenter, active-controlled
trial to compare the efficacy and safety of HALAVEN® in patients
with advanced liposarcoma or leiomyosarcoma4,5
THE PHASE III STUDY 309: MULTICENTER, RANDOMIZED, OPEN-LABEL4,5
Patients with unresectable,
locally advanced or metastatic liposarcoma
or leiomyosarcoma (N=446)
• ≥2 prior chemotherapy
regimens, 1 of which
must have been
an anthracycline
HALAVEN
(n=225)
1.4 mg/m2 IV for
2 to 5 minutes
Days 1 and 8
(21-day cycle)
PRIMARY
ENDPOINT:
OS
RANDOMIZATION (1:1)a
DACARBAZINE
(Control arm, n=221)b
850 mg/m2,
1,000 mg/m2,
or 1,200 mg/m2
every 21 days
• Disease progression within
6 months of the most recent
chemotherapy regimen
Selected
Secondary Endpoint
PFS
IV=intravenous.
Randomization was stratified by histology (liposarcoma or leiomyosarcoma), number of prior therapies, and geographic region.
b
Dose determined by the investigator prior to randomization.
a
The FDA recognizes overall survival as the most reliable
and preferred clinical endpoint in cancer trials20
BASELINE CHARACTERISTICS4
LIPOSARCOMA STRATUM
(n=143)
SELECTED PATIENT FACTORS
Median age
Sex
ECOG PS
Prior systemic chemotherapies
Liposarcoma
histological subtype
55 years
Female
38%
0
41%
1
53%
>2
44%
Dedifferentiated
45%
Myxoid/round cell
37%
Pleomorphic
18%
ECOG PS=Eastern Cooperative Oncology Group performance status.
16
Please see Important Safety Information throughout
and accompanying HALAVEN full Prescribing Information.
HALAVEN was studied in patients with
advanced liposarcoma or leiomyosarcoma
and with intermediate-to-high tumor grades5
BASELINE PATIENT CHARACTERISTICS5,21
HALAVEN
DACARBAZINE
(n=228)
(n=224)
<65 years
78%
79%
≥65 years
22%
21%
Female
71%
63%
0
49%
40%
1
50%
54%
2
1%
6%
Liposarcoma
33%
35%
Leiomyosarcoma
67%
65%
Dedifferentiated
14%
17%
Myxoid/round cell
13%
12%
6%
7%
Uterine
30%
28%
Nonuterine
36%
37%
Unknown
<1%
0%
High
66%
68%
Intermediate
34%
31%
Not known
<1%
1%
1
7%
6%
2
51%
44%
>2
42%
50%
SELECTED PATIENT FACTORS
Age
Sex
ECOG PS
Histology
Liposarcoma
histological subtype
Leiomyosarcoma
primary site
Tumor grade
Number of prior regimens for
advanced disease
Pleomorphic
A treatment option for patients with advanced liposarcoma4,5
Who have received a prior anthracycline-containing regimen
ith intermediate-to-high tumor grades regardless of
W
liposarcoma subtype
17
Safety profile demonstrated in the pivotal
Phase III trial in advanced liposarcoma
and leiomyosarcoma
ADVERSE REACTIONS4,a
Occurring in ≥10% (all Grades) of patients treated in the HALAVEN arm and at a higher incidence
than in the dacarbazine arm (between-arm difference of ≥5% for all Grades or ≥2% for Grades 3 and 4)b
HALAVEN
DACARBAZINE
(n=223)
(n=221)
All
3-4
All
3-4
Peripheral neuropathyc
29%
3.1%
8%
0.5%
Headache
18%
0%
10%
0%
Pyrexia
28%
0.9%
14%
0.5%
32%
0.9%
26%
0.5%
Abdominal pain
29%
1.8%
23%
4.1%
Stomatitis
14%
0.9%
5%
0.5%
Skin and subcutaneous
tissue disorders
Alopecia
35%
NAe
2.7%
NAe
Infections
Urinary tract infection
11%
2.2%
5%
0.5%
ADVERSE REACTION BY GRADE
Nervous system disorders
General disorders
Constipation
Gastrointestinal disorders
d
Adverse reactions were graded per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
Safety data from 1 study site enrolling 6 patients were excluded.
c
Includes peripheral neuropathy, peripheral sensorimotor neuropathy, peripheral motor neuropathy, polyneuropathy, peripheral sensory neuropathy, and paresthesia.
d
Includes abdominal pain, upper abdominal pain, lower abdominal pain, and abdominal discomfort.
e
Not applicable; grading system does not specify greater than Grade 2 for alopecia.
a
b
Other clinically important adverse reactions occurring in ≥10% of the HALAVEN-treated
patients were nausea (41%), vomiting (19%), diarrhea (17%), asthenia/fatigue (62%),
peripheral edema (12%), decreased appetite (19%), arthralgia/myalgia (16%), back pain
(16%), and cough (18%)4
The median duration of exposure was 2.3 months (range: 21 days to 26 months) for
patients receiving HALAVEN4
18
Please see additional Important Safety Information throughout
and accompanying HALAVEN full Prescribing Information.
Laboratory abnormalities in the
Phase III trial
LABORATORY ABNORMALITIES4,f,g
Occurring in ≥10% (all Grades) of patients treated in the HALAVEN arm and at a higher incidence than
in the dacarbazine arm (between-arm difference of ≥5% for all Grades or ≥2% for Grades 3 and 4)
HALAVEN
All
3-4
All
Anemia
70%
4.1%
52%
6%
Neutropenia
63%
32%
30%
8.9%
Increased alanine
aminotransferase
43%
2.3%
28%
2.3%
Increased aspartate
aminotransferase
36%
0.9%
16%
0.5%
Hypokalemia
30%
5.4%
14%
2.8%
Hypocalcemia
28%
5%
18%
1.4%
Hypophosphatemia
20%
3.2%
11%
1.4%
LABORATORY ABNORMALITY BY GRADE
Hematology
Chemistry
DACARBAZINE
3-4
Each test incidence is based on the number of patients who had both baseline and at least 1 on-study measurement and at least 1 grade increase from baseline.
HALAVEN group (range 221-222) and dacarbazine group (range 214-215).
g
Laboratory results were graded per NCI CTCAE version 4.03.
f
19
One consistent dose and schedule for mBC
and advanced liposarcoma
Quick 2- to 5-minute IV infusion4
RECOMMENDED HALAVEN ADMINISTRATION4
DOSE
INFUSION TIME
SCHEDULE
2 to 5
minutes
Days 1 and 8
(21-day cycle)
1.4 mg/m2
Recommended dose
In patients with
1.1 mg/m2
• Mild hepatic impairmenta
• Moderate hepatic impairmentb
0.7 mg/m2
• Moderate or severe renal impairmentc
1.1 mg/m2
Mild hepatic impairment=Child-Pugh A.
Moderate hepatic impairment=Child-Pugh B.
c
Creatinine clearance (CLcr) of 15-49 mL/min.
a
b
Patients with severe hepatic impairment (Child-Pugh C) were not studied4
Straightforward preparation
Administer undiluted or diluted
HALAVEN may be diluted in 100 mL of 0.9% Sodium Chloride Injection, USP4
Do not dilute in or administer through an intravenous line containing solutions with
dextrose. Do not administer in the same intravenous line with other medicinal products4
HALAVEN is not formulated in solvents such as Cremophor® or polysorbate 8021
No known drug-drug interactions4
No premedication required21
No premixing required4
Assess for peripheral neuropathy and obtain complete blood cell counts prior
to each dose4
Cremophor® EL Castor Oil is a registered trademark of BASF Corporation or BASF SE.
20
Please see Important Safety Information throughout
and accompanying HALAVEN full Prescribing Information.
Recommended dose modifications
Recommended dose delays4*
Do not administer HALAVEN on Day 1 or Day 8 in patients with ≥Grade 3 neutropenia,†
≥Grade 2 thrombocytopenia,‡ or Grade 3/4 nonhematologic toxicities
The Day 8 dose may be delayed for up to 1 week in patients with toxicities
— If toxicities resolve or improve to Grade 2 or less by Day 15, administer at a reduced
dose and initiate the next cycle no sooner than 2 weeks later
— If toxicities do not resolve or improve to Grade 2 or less by Day 15, omit the dose
If a dose has been delayed for toxicities that have recovered to a severity of Grade 2
or less, resume at the recommended reduced dose
If a dose has been reduced due to toxicities, do not re-escalate
RECOMMENDED DOSE REDUCTIONS4*
CURRENT DOSE
RECOMMENDED
DOSE REDUCTION
1.4 mg/m2
1.1 mg/m2
Any event requiring permanent dose reduction while
receiving 1.1 mg/m2
1.1 mg/m2
0.7 mg/m2
Any event requiring permanent dose reduction while
receiving 0.7 mg/m2
0.7 mg/m2
Discontinue
HALAVEN
EVENTS REQUIRING PERMANENT DOSE REDUCTION
Hematologic toxicities
• ANC <500/mm3 for >7 days or ANC <1,000/mm3 with
fever or infection
• Platelets <25,000/mm3 or platelets <50,000/mm3
requiring transfusion
Grade 3/4 nonhematologic toxicities
Omission or delay of Day 8 dose in previous cycle for toxicity
DOSING AND
ADMINISTRATION
ANC=absolute neutrophil count.
*Toxicities graded in accordance with NCI CTCAE version 3.0.4
†
‡
Greater than or equal to Grade 3 neutropenia=ANC <1,000/mm3.24
Greater than or equal to Grade 2 thrombocytopenia=platelets <75,000/mm3.24
21
HALAVEN® $0 Co-Pay Program
Simplified paperwork—no income requirements
The HALAVEN $0 Co-Pay Program assists eligible patients with the out-of-pocket costs of
HALAVEN (up to $18,000 per year).
To qualify,* patients must
Be covered by commercial insurance
Not be enrolled in state or federal health care programs, including Medicare,
Medicaid, Medigap, VA, DoD, or TRICARE
*Other eligibility requirements may apply.
HALAVEN® $0 Co-Pay Program
HALAVEN $0 Co-Pay Program • Phone: 1-866-61-EISAI (1-866-613-4724) • Fax: 1-844-745-2350
2250 Perimeter Park Drive, Suite 300 • Morrisville, North Carolina 27560
Your Patient Information Card
HALAVEN® is a registered trademark used by Eisai Inc. under license from Eisai R&D Management Co., Ltd.
©2016 Eisai Inc. All rights reserved. Printed in USA May 2016 HALA-US0403(1)
Welcome to the HALAVEN® (eribulin mesylate) injection $0 Co-Pay Program.
To the Patient: Present this HALAVEN $0 Co-Pay Card to your healthcare provider to participate in this program. Commercially
insured patients will pay no more than $0. Maximum benefit paid by Eisai Inc. will be $18,000 per year. Depending on your insurance
plan, you could have additional financial responsibility for any amounts over Eisai's maximum liability. For questions, please call
1-866-61-EISAI (1-866-613-4724).
To the Health Care Provider: In order for the patient to receive a rebate, you or the patient must submit an Explanation of Benefits
(EOB) from the primary insurance provider (as well as any secondary insurance provider) or the Specialty Pharmacy Provider receipt
after every infusion, either by mail to the address at the top of this card or by fax to 1-844-745-2350. Once we receive and process
the patient’s EOB or Specialty Pharmacy receipt, we will fax your site a virtual debit card loaded with the patient’s savings. If you
indicated on the patient’s enrollment form that your site does not accept Debit Card Payment or if the patient uses a specialty
pharmacy to purchase HALAVEN, we will instead provide a rebate check to the patient. For questions, please call 1-866-61-EISAI
(1-866-613-4724).
Eligibility Criteria: Good toward the purchase of HALAVEN prescriptions. No substitutions permitted. Not available to patients
enrolled in state and federal healthcare programs, including Medicare, Medicaid, Medigap, VA, DoD or TRICARE. Offer available to
MA residents through June 30, 2017. Offer only available to patients with private, commercial insurance. May not be combined with
any other coupon, discount, prescription savings card, free trial or other offer. Federal law prohibits the selling, purchasing, trading,
or counterfeiting of this card. Such activities may result in imprisonment of 10 years, fines up to $25,000, or both. Void outside the
USA and where prohibited by law. Eisai Inc. reserves the right to rescind, revoke, or amend this offer at any time without notice.
Patients and pharmacies are responsible for disclosing to insurance carriers the redemption and value of the card and complying
with any other conditions imposed by insurance carriers on third-party payers. The value of this card is not contingent on any prior
or future purchases. The card is solely intended to provide savings on any purchase of HALAVEN. Use of the card for any one
purchase does not obligate the patient to make future purchases of HALAVEN. This offer will expire November 20, 2019.
Learn more about the HALAVEN $0 Co-Pay Program
and the Eisai Assistance Program for HALAVEN
by visiting www.eisaireimbursement.com/hcp/halaven
or calling 1.866.61.EISAI (1.866.613.4724)
Monday-Friday, 8 am to 8 pm, ET
HALAVEN® is a registered trademark used by Eisai Inc. under license from Eisai R&D Management Co., Ltd.
©2016 Eisai Inc. All rights reserved. Printed in USA May 2016 HALA-US0403(1)
22
Please see Important Safety Information throughout
and accompanying HALAVEN full Prescribing Information.
The Eisai Assistance Program for HALAVEN
Reimbursement services
Reimbursement information, complete with details on coding, including utilizing
the HALAVEN J-code, J9179†
Insurance verification and coverage options with an approximate
24- to 48-hour turnaround for all queries
Support in evaluating alternate coverage options and advising on
application requirements
Prior authorization assistance with researching requirements and individual
payer instructions
Claims assistance in evaluating denials
Educating payers about HALAVEN billing and the appeal process
Patient assistance and free product to eligible patients
Eisai cannot guarantee payment of any claim. Coding, coverage, and reimbursement may vary significantly by payer, plan, patient, and setting of care. Actual
coverage and reimbursement decisions are made by individual payers following the receipt of claims. For additional information, customers should consult with
their payers for all relevant coding, reimbursement, and coverage requirements. It is the sole responsibility of the provider to select the proper code and ensure the
accuracy of all claims used in seeking reimbursement. All services must be medically appropriate and properly supported in the patient medical record.
†
References: 1. Cortes J, O’Shaughnessy J, Loesch D, et al. EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician’s Choice Versus E7389)
investigators. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label
randomised study. Lancet. 2011;377(9769):914-923. 2. Saad ED, Katz A, Buyse M. Overall survival and post-progression survival in advanced breast cancer:
a review of recent randomized clinical trials. J Clin Oncol. 2010;28(11):1958-1962. 3. Sparano JA, Vrdoljak E, Rixe O, et al. Randomized phase III trial of
ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol.
2010;28(20):3256-3263. 4. HALAVEN [package insert]. Woodcliff Lake, NJ: Eisai Inc; 2016. 5. Schöffski P, Chawla S, Maki RG, et al. Eribulin versus dacarbazine
in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016;387(10028):1629-1637.
6. Towle MJ, Salvato KA, Budrow J, et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res.
2001;61(3):1013-1021. 7. Jordan MA, Kamath K, Manna T, et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of
microtubule growth. Mol Cancer Ther. 2005;4(7):1086-1095. 8. Towle MJ, Salvato KA, Wels BF, et al. Eribulin induces irreversible mitotic blockade: implications of
cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Res. 2011;71(2):496-505. 9. Kuznetsov G, Towle MJ, Cheng H, et al.
Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res.
2004;64(16):5760-5766. 10. Smith JA, Wilson L, Azarenko O, et al. Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability.
Biochemistry. 2010;49(6):1331-1337. 11. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4(4):253-265.
12. Yoshida T, Ozawa Y, Kimura T, et al. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial–
mesenchymal transition (EMT) to mesenchymal–epithelial transition (MET) states. Br J Cancer. 2014;110(6):1497-1505. 13. Funahashi Y, Okamoto K, Adachi Y, et al.
Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. Cancer Sci.
2014;105(10):1334-1342. 14. Dybdal-Hargreaves NF, Risinger AL, Mooberry SL. Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent.
Clin Cancer Res. 2015;21(11):2445-2452. 15. Jiang J, Tang YL, Liang XH. EMT: a new vision of hypoxia promoting cancer progression. Cancer Biol Ther. 2011;11(8):714-723.
16. Planchat E, Abrial C, Thivat E, et al. Late lines of treatment benefit survival in metastatic breast cancer in current practice? Breast. 2011;20(6):574-578.
17. CancerMPact®. Kantar Health. Treatment Architecture: Western Europe Breast Cancer, v1.2. Available from www.cancermpact.com. Published January 2015.
Updated May 2015. 18. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.2.2016.
© 2016 National Comprehensive Cancer Network, Inc. All rights reserved. Accessed August 24, 2016. To view the most recent and complete version of the
guideline, go online to NCCN.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks
owned by the National Comprehensive Cancer Network, Inc. 19. NCI dictionary of cancer terms. National Cancer Institute Web site. http://www.cancer.gov/
publications/dictionaries/cancer-terms?CdrID=618612. Accessed August 24, 2016. 20. U.S. Department of Health and Human Services, Food and Drug
Administration. Guidance for Industry: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. http://www.fda.gov/downloads/Drugs/
guidancecomplianceregulatoryinformation/guidances/ucm071590.pdf. Published May 2007. Accessed August 24, 2016. 21. Data on file, Eisai Inc.
22. Tseng WW, Somaiah N, Lazar AJ, Lev DC, Pollock RE. Novel systemic therapies in advanced liposarcoma: a review of recent clinical trial results. Cancers
(Basel). 2013;5(2):529-549. 23. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Soft Tissue
Sarcoma V.2.2016. © 2016 National Comprehensive Cancer Network, Inc. All rights reserved. Accessed August 24, 2016. To view the most recent and complete
version of the guideline, go online to NCCN.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content
are trademarks owned by the National Comprehensive Cancer Network, Inc. 24. National Cancer Institute. Cancer Therapy Evaluation Program, Common
Terminology Criteria for Adverse Events v3.0. NIH Publication # 03-5410. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf.
Published March 31, 2003. Updated August 9, 2006. Accessed August 24, 2016.
REIMBURSEMENT/
REFERENCES
23
Significant overall survival benefit
TWICE PROVEN: and
consistent safety profile
4
MEDIAN OS4
HALAVEN
mBC: following 2
prior mBC therapies
(primary analysis)
13.1 months
Advanced liposarcoma
15.6 months
CONTROL ARM
(95% CI)
(n=508)
(11.8, 14.3)
(n=71)
(10.2, 18.6)
Tumor types4
m
BC: following 2 prior mBC
therapies
Advanced liposarcoma
(95% CI)
HAZARD RATIO
(TPC, n=254)
10.6 months
(9.3, 12.5)
(dacarbazine, n=72)
8.4 months
(5.2, 10.1)
(95% CI)
0.81
(0.66, 0.99)
0.51
(0.35, 0.75)
Consistent dose
and schedule4
Q
uick 2- to 5-minute IV infusion:
administered on Days 1 and 8 of a 21-day cycle
Established dose modification schedule
Proven clinical-trial and real-world experience 4,21
Prescribed to approximately 40,000 patients with mBC in the United States
The first agent in the halichondrin class6
Based on preclinical studies, HALAVEN exerts its effects through its distinct binding profile4,7
HALAVEN showed biological effects on tumor vascularization and microenvironment in human
cancer models in vivo. HALAVEN also showed decreased migration and invasiveness of cancer
cells in vitro4,5
For more information, please visit www.halaven.com
OS=overall survival; CI=confidence interval; mBC=metastatic breast cancer; TPC=Treatment of Physician’s Choice; IV=intravenous.
Important Safety Information (continued)
Hepatic and Renal Impairment: A reduction in starting dose is recommended for patients with
mild or moderate hepatic impairment and/or moderate or severe renal impairment.
Please see additional Important Safety Information throughout
and accompanying HALAVEN full Prescribing Information.
HALAVEN® is a registered trademark used by Eisai Inc. under license from Eisai R&D Management Co., Ltd.
© 2016 Eisai Inc.
All rights reserved.
Printed in USA/September 2016
HALA-US0218(2)a
HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use HALAVEN safely and
effectively. See full prescribing information for HALAVEN.
HALAVEN® (eribulin mesylate) injection, for intravenous use
Initial U.S. Approval: 2010
RECENT MAJOR CHANGES
Indications and Usage (1.2)
Warnings and Precautions (5.1, 5.2, 5.3)
01/2016
01/2016
INDICATIONS AND USAGE
HALAVEN is a microtubule inhibitor indicated for the treatment of patients with:
• Metastatic breast cancer who have previously received at least two chemotherapeutic regimens
for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a
taxane in either the adjuvant or metastatic setting. (1.1)
• Unresectable or metastatic liposarcoma who have received a prior anthracycline-containing
regimen. (1.2)
DOSAGE AND ADMINISTRATION
• Administer 1.4 mg/m2 intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle. (2.1)
• Reduce dose in patients with hepatic impairment or with moderate or severe renal impairment. (2.1)
• Do not mix with other drugs or administer with dextrose-containing solutions. (2.3)
DOSAGE FORMS AND STRENGTHS
Injection: 1 mg per 2 mL (0.5 mg per mL) (3)
None (4)
CONTRAINDICATIONS
FULL PRESCRIBING INFORMATION: CONTENTS*
1 INDICATIONS AND USAGE
1.1 Metastatic Breast Cancer
1.2 Liposarcoma
2 DOSAGE AND ADMINISTRATION
2.1 Recommended Dose
2.2 Dose Modification
2.3 Instructions for Preparation and Administration
3 DOSAGE FORMS AND STRENGTHS
4 CONTRAINDICATIONS
5 WARNINGS AND PRECAUTIONS
5.1 Neutropenia
5.2 Peripheral Neuropathy
5.3 Embryo-Fetal Toxicity
5.4 QT Prolongation
6 ADVERSE REACTIONS
6.1 Clinical Trials Experience
6.2 Postmarketing Experience
7 DRUG INTERACTIONS
7.1 Effects of Other Drugs on HALAVEN
7.2 Effects of HALAVEN on Other Drugs
FULL PRESCRIBING INFORMATION
1 INDICATIONS AND USAGE
1.1 Metastatic Breast Cancer
HALAVEN is indicated for the treatment of patients with metastatic breast cancer who have
previously received at least two chemotherapeutic regimens for the treatment of metastatic
disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant
or metastatic setting [see Clinical Studies (14.1)].
1.2 Liposarcoma
HALAVEN is indicated for the treatment of patients with unresectable or metastatic liposarcoma
who have received a prior anthracycline-containing regimen [see Clinical Studies (14.2)].
2 DOSAGE AND ADMINISTRATION
2.1 Recommended Dose
The recommended dose of HALAVEN is 1.4 mg/m2 administered intravenously over 2 to 5
minutes on Days 1 and 8 of a 21-day cycle.
The recommended dose of HALAVEN in patients with mild hepatic impairment (Child-Pugh A) is
1.1 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle
[see Use in Specific Populations (8.6)].
The recommended dose of HALAVEN in patients with moderate hepatic impairment (Child-Pugh B)
is 0.7 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle
[see Use in Specific Populations (8.6)].
The recommended dose of HALAVEN in patients with moderate or severe renal impairment
(creatinine clearance (CLcr) 15-49 mL/min) is 1.1 mg/m2 administered intravenously over
2 to 5 minutes on Days 1 and 8 of a 21-day cycle [see Use in Specific Populations (8.7)].
2.2 Dose Modification
Assess for peripheral neuropathy and obtain complete blood cell counts prior to each dose.
Recommended dose delays
• Do not administer HALAVEN on Day 1 or Day 8 for any of the following:
– ANC < 1,000/mm3
– Platelets < 75,000/mm3
– Grade 3 or 4 non-hematological toxicities.
• The Day 8 dose may be delayed for a maximum of 1 week.
– If toxicities do not resolve or improve to ≤ Grade 2 severity by Day 15, omit the dose.
WARNINGS AND PRECAUTIONS
• Neutropenia: Monitor peripheral blood cell counts and adjust dose as appropriate. (5.1)
• Peripheral Neuropathy: Monitor for signs of neuropathy. Manage with dose delay and
adjustment. (5.2)
• Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of the
potential risk to the fetus and to use effective contraception. (5.3, 8.1, 8.3)
• QT Prolongation: Monitor for prolonged QT intervals in patients with congestive heart failure,
bradyarrhythmias, drugs known to prolong the QT interval, and electrolyte abnormalities. Avoid
in patients with congenital long QT syndrome. (5.4)
ADVERSE REACTIONS
The most common adverse reactions (≥25%) in metastatic breast cancer were neutropenia, anemia,
asthenia/fatigue, alopecia, peripheral neuropathy, nausea, and constipation. (6.1)
The most common adverse reactions (≥25%) in liposarcoma and leiomyosarcoma were fatigue,
nausea, alopecia, constipation, peripheral neuropathy, abdominal pain, and pyrexia. The most
common (≥5%) Grade 3-4 laboratory abnormalities in liposarcoma and leiomyosarcoma were
neutropenia, hypokalemia, and hypocalcemia. (6.1)
To report SUSPECTED ADVERSE REACTIONS, contact Eisai Inc. at (1-877-873-4724) or FDA
at 1-800-FDA-1088 or www.fda.gov/medwatch
USE IN SPECIFIC POPULATIONS
• Lactation: Do not breastfeed. (8.2)
• Hepatic Impairment: A lower starting dose is recommended for patients with mild
(Child-Pugh A) and moderate (Child-Pugh B) hepatic impairment. Patients with severe
hepatic impairment (Child-Pugh C) were not studied. (8.6)
• Renal Impairment: A lower starting dose is recommended for patients with moderate
(CLcr 30-49 mL/min) or severe (CLcr 15-29 mL/min) renal impairment. (8.7)
See 17 for PATIENT COUNSELING INFORMATION and FDA-approved Patient Labeling
(Patient Information).
Revised: October 2016
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
8.2 Lactation
8.3 Females and Males of Reproductive Potential
8.4 Pediatric Use
8.5 Geriatric Use
8.6 Hepatic Impairment
8.7 Renal Impairment
10 OVERDOSAGE
11 DESCRIPTION
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
12.2 Pharmacodynamics
12.3 Pharmacokinetics
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
14 CLINICAL STUDIES
14.1 Metastatic Breast Cancer
14.2 Liposarcoma
16 HOW SUPPLIED/STORAGE AND HANDLING
17 PATIENT COUNSELING INFORMATION
*Sections or subsections omitted from the full prescribing information are not listed.
– If toxicities resolve or improve to ≤ Grade 2 severity by Day 15, administer HALAVEN at a
reduced dose and initiate the next cycle no sooner than 2 weeks later.
Recommended dose reductions
• If a dose has been delayed for toxicity and toxicities have recovered to Grade 2 severity or
less, resume HALAVEN at a reduced dose as set out in Table 1.
• Do not re-escalate HALAVEN dose after it has been reduced.
Table 1: Recommended Dose Reductions
Event Description
Recommended
HALAVEN Dose
Permanently reduce the 1.4 mg/m2 HALAVEN dose
for any of the following:
ANC <500/mm3 for >7 days
ANC <1,000 /mm3 with fever or infection
Platelets <25,000/mm3
1.1 mg/m2
Platelets <50,000/mm3 requiring transfusion
Non-hematologic Grade 3 or 4 toxicities
Omission or delay of Day 8 HALAVEN dose in previous
cycle for toxicity
Occurrence of any event requiring permanent dose reduction
0.7 mg/m2
while receiving 1.1 mg/m2
Occurrence of any event requiring permanent dose reduction
Discontinue HALAVEN
while receiving 0.7 mg/m2
ANC = absolute neutrophil count.
Toxicities graded in accordance with National Cancer Institute (NCI) Common Terminology
Criteria for Adverse Events (CTCAE) version 3.0.
2.3 Instructions for Preparation and Administration
Aseptically withdraw the required amount of HALAVEN from the single-use vial and
administer undiluted or diluted in 100 mL of 0.9% Sodium Chloride Injection, USP.
Do not dilute in or administer through an intravenous line containing solutions
with dextrose. Do not administer in the same intravenous line concurrent with the other
medicinal products.
3
4
5
6
Store undiluted HALAVEN in the syringe for up to 4 hours at room temperature or for up to 24
hours under refrigeration (40°F or 4°C). Store diluted solutions of HALAVEN for up to 4 hours at
room temperature or up to 24 hours under refrigeration.
Discard unused portions of the vial.
DOSAGE FORMS AND STRENGTHS
Injection: 1 mg/2 mL (0.5 mg/mL).
CONTRAINDICATIONS
None.
WARNINGS AND PRECAUTIONS
5.1 Neutropenia
In Study 1, severe neutropenia (ANC < 500/mm3) lasting more than one week occurred in 12%
(62/503) of patients with metastatic breast cancer, leading to discontinuation in <1% of patients.
Febrile neutropenia (fever ≥38.5°C with Grade 3 or 4 neutropenia) occurred in 5% (23/503)
of patients; two patients (0.4%) died from complications of febrile neutropenia [see Adverse
Reactions (6.1)].
In Study 1, patients with alanine aminotransferase (ALT) or aspartate aminotransferase (AST)
> 3 × ULN (upper limit of normal) experienced a higher incidence of Grade 4 neutropenia
and febrile neutropenia than patients with normal aminotransferase levels. Patients with
bilirubin > 1.5 × ULN also had a higher incidence of Grade 4 neutropenia and febrile neutropenia.
In Study 2, severe neutropenia (ANC < 500/mm3) lasting more than one week occurred in 12%
(26/222) of patients with liposarcoma or leiomyosarcoma. Febrile neutropenia occurred in 0.9% of
patients treated with HALAVEN and fatal neutropenic sepsis in 0.9% [see Adverse Reactions (6.1)].
Monitor complete blood counts prior to each dose; increase the frequency of monitoring in
patients who develop Grade 3 or 4 cytopenias. Delay administration of HALAVEN and reduce
subsequent doses in patients who experience febrile neutropenia or Grade 4 neutropenia lasting
longer than 7 days [see Dosage and Administration (2.2)]. Clinical studies of HALAVEN did not
include patients with baseline neutrophil counts below 1,500/mm3.
5.2 Peripheral Neuropathy
In Study 1, Grade 3 peripheral neuropathy occurred in 8% (40/503) of patients, and Grade 4 in
0.4% (2/503) of patients with metastatic breast cancer (MBC). Peripheral neuropathy was the
most common toxicity leading to discontinuation of HALAVEN (5% of patients; 24/503) in Study 1.
Neuropathy lasting more than one year occurred in 5% (26/503) of patients. Twenty-two percent
(109/503) of patients developed a new or worsening neuropathy that had not recovered within a
median follow-up duration of 269 days (range 25-662 days).
In Study 2, Grade 3 peripheral neuropathy occurred in 3.1% (7/223) of HALAVEN-treated
patients. Peripheral neuropathy led to discontinuation of HALAVEN in 0.9% of patients. The
median time to first occurrence of peripheral neuropathy of any severity was 5 months (range:
3.5 months to 9 months). Neuropathy lasting more than 60 days occurred in 58% (38/65) of
patients. Sixty three percent (41/65) had not recovered within a median follow-up duration of
6.4 months (range: 27 days to 29 months).
Monitor patients closely for signs of peripheral motor and sensory neuropathy. Withhold
HALAVEN in patients who experience Grade 3 or 4 peripheral neuropathy, until resolution to
Grade 2 or less [see Dosage and Administration (2.2)].
5.3 Embryo-Fetal Toxicity
Based on findings from an animal reproduction study and its mechanism of action, HALAVEN
can cause fetal harm when administered to a pregnant woman. There are no adequate and
well-controlled studies of HALAVEN in pregnant women. In animal reproduction studies, eribulin
mesylate caused embryo-fetal toxicity when administered to pregnant rats during organogenesis
at doses below the recommended human dose. Advise pregnant women of the potential risk to
a fetus. Advise females of reproductive potential to use effective contraception during treatment
with HALAVEN and for at least 2 weeks following the final dose. Advise males with female
partners of reproductive potential to use effective contraception during treatment with HALAVEN
and for 3.5 months following the final dose [see Use in Specific Populations (8.1)].
5.4 QT Prolongation
In an uncontrolled open-label ECG study in 26 patients, QT prolongation was observed on
Day 8, independent of eribulin concentration, with no QT prolongation observed on Day 1.
ECG monitoring is recommended if therapy is initiated in patients with congestive heart
failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III
antiarrhythmics, and electrolyte abnormalities. Correct hypokalemia or hypomagnesemia
prior to initiating HALAVEN and monitor these electrolytes periodically during therapy.
Avoid HALAVEN in patients with congenital long QT syndrome.
ADVERSE REACTIONS
6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, the adverse reaction rates
observed in the clinical trials of a drug cannot be directly compared to rates in other clinical trials
and may not reflect the rates observed in clinical practice.
The following adverse reactions are discussed in detail in other sections of the labeling:
• Neutropenia [see Warnings and Precautions (5.1)]
• Peripheral neuropathy [see Warnings and Precautions (5.2)]
• QT prolongation [see Warnings and Precautions (5.4)]
In clinical trials, HALAVEN has been administered to 1963 patients including 467 patients
exposed to HALAVEN for 6 months or longer. The majority of the 1963 patients were women
(92%) with a median age of 55 years (range: 17 to 85 years). The racial and ethnic distribution
was White (72%), Black (4%), Asian (9%), and other (3%).
Metastatic Breast Cancer
The most common adverse reactions (≥25%) reported in patients receiving HALAVEN
were neutropenia, anemia, asthenia/fatigue, alopecia, peripheral neuropathy, nausea, and
constipation. The most common serious adverse reactions reported in patients receiving
HALAVEN were febrile neutropenia (4%) and neutropenia (2%). The most common adverse
reaction resulting in discontinuation of HALAVEN was peripheral neuropathy (5%).
The adverse reactions described in Table 2 were identified in 750 patients treated in Study 1
[see Clinical Studies (14.1)]. In Study 1, patients were randomized (2:1) to receive either
HALAVEN (1.4 mg/m2 on Days 1 and 8 of a 21-day cycle) or single agent treatment chosen by
their physician (control group). A total of 503 patients received HALAVEN and 247 patients in
the control group received therapy consisting of chemotherapy [total 97% (anthracyclines 10%,
capecitabine 18%, gemcitabine 19%, taxanes 15%, vinorelbine 25%, other chemotherapies
10%)] or hormonal therapy (3%). The median duration of exposure was 118 days for patients
receiving HALAVEN and 63 days for patients receiving control therapy. Table 2 reports the most
common adverse reactions occurring in at least 10% of patients in either group.
Table 2: Adverse Reactionsa with a Per-Patient Incidence of at Least 10% in Study 1
HALAVEN
Control Group
n=503
n=247
All Grades ≥ Grade 3 All Grades ≥ Grade 3
Blood and lymphatic system disordersb
Neutropenia
82%
57%
53%
23%
Anemia
58%
2%
55%
4%
Nervous system disorders
Peripheral neuropathyc
35%
8%
16%
2%
Headache
19%
<1%
12%
<1%
General disorders
Asthenia/Fatigue
54%
10%
40%
11%
Pyrexia
21%
<1%
13%
<1%
Mucosal inflammation
9%
1%
10%
2%
Gastrointestinal disorders
Nausea
35%
1%
28%
3%
Constipation
25%
1%
21%
1%
Vomiting
18%
1%
18%
1%
Diarrhea
18%
0
18%
0
Musculoskeletal and connective tissue disorders
Arthralgia/Myalgia
22%
<1%
12%
1%
Back pain
16%
1%
7%
2%
Bone pain
12%
2%
9%
2%
Pain in extremity
11%
1%
10%
1%
Metabolism and nutrition disorders
Decreased weight
21%
1%
14%
<1%
Anorexia
20%
1%
13%
1%
Respiratory, thoracic, and mediastinal disorders
Dyspnea
16%
4%
13%
4%
Cough
14%
0
9%
0
Skin and subcutaneous tissue disorders
Alopecia
45%
NAd
10%
NAd
Infections
Urinary Tract Infection
10%
1%
5%
0
a
adverse reactions were graded per National Cancer Institute Criteria for Adverse Events version 4.0.
b
based upon laboratory data.
c
includes peripheral neuropathy, peripheral sensorimotor neuropathy, peripheral motor
neuropathy, polyneuropathy, peripheral sensory neuropathy, and paraesthesia.
d
not applicable; (grading system does not specify > Grade 2 for alopecia).
Adverse Reactions
Cytopenias: Grade 3 neutropenia occurred in 28% (143/503) of patients who received HALAVEN
in Study 1, and 29% (144/503) of patients experienced Grade 4 neutropenia. Febrile neutropenia
occurred in 5% (23/503) of patients; two patients (0.4%) died from complications of febrile
neutropenia. Dose reduction due to neutropenia was required in 12% (62/503) of patients and
discontinuation was required in <1% of patients. The mean time to nadir was 13 days and the
mean time to recovery from severe neutropenia (<500/mm3) was 8 days. Grade 3 or greater
thrombocytopenia occurred in 1% (7/503) of patients. G-CSF (granulocyte colony-stimulating
factor) or GM-CSF (granulocyte–macrophage colony-stimulating factor) was used in 19% of
patients who received HALAVEN.
Peripheral Neuropathy: In Study 1, 17% of enrolled patients had Grade 1 peripheral neuropathy
and 3% of patients had Grade 2 peripheral neuropathy at baseline. Dose reduction due to
peripheral neuropathy was required by 3% (14/503) of patients who received HALAVEN. Four
percent (20/503) of patients experienced peripheral motor neuropathy of any grade and 2%
(8/503) of patients developed Grade 3 peripheral motor neuropathy.
Liver Function Test Abnormalities: Among patients with Grade 0 or 1 ALT levels at baseline,
18% of HALAVEN-treated patients experienced Grade 2 or greater ALT elevation. One HALAVENtreated patient without documented liver metastases had concomitant Grade 2 elevations in
bilirubin and ALT; these abnormalities resolved and did not recur with re-exposure to HALAVEN.
Less Common Adverse Reactions: The following additional adverse reactions were reported in
≥5% to <10% of the HALAVEN-treated group:
• Eye Disorders: increased lacrimation
• Gastrointestinal Disorders: dyspepsia, abdominal pain, stomatitis, dry mouth
• General Disorders and Administration Site Conditions: peripheral edema
• Infections and Infestations: upper respiratory tract infection
• Metabolism and Nutrition Disorders: hypokalemia
• Musculoskeletal and Connective Tissue Disorders: muscle spasms, muscular weakness
• Nervous System Disorders: dysgeusia, dizziness
• Psychiatric Disorders: insomnia, depression
• Skin and Subcutaneous Tissue Disorders: rash
Liposarcoma
The safety of HALAVEN was evaluated in Study 2, an open-label, randomized, multicenter,
active-controlled trial, in which patients were randomized (1:1) to receive either HALAVEN
1.4 mg/m2 on Days 1 and 8 of a 21-day cycle or dacarbazine at doses of 850 mg/m2 (20%),
1000 mg/m2 (64%), or 1200 mg/m2 (16%) every 3 weeks. A total of 223 patients received HALAVEN
and 221 patients received dacarbazine. Patients were required to have received at least two
prior systemic chemotherapy regimens. The trial excluded patients with pre-existing ≥ Grade 3
peripheral neuropathy, known central nervous system metastasis, elevated serum bilirubin or
significant chronic liver disease, history of myocardial infarction within 6 months, history of
New York Heart Association Class II or IV heart failure, or cardiac arrhythmia requiring treatment.
The median age of the safety population in Study 2 was 56 years (range: 24 to 83 years);
67% female; 73% White, 3% Black or African American, 8% Asian/Pacific Islander, and
15% unknown; 99% received prior anthracycline-containing regimen; and 99% received ≥ 2 prior
regimens. The median duration of exposure was 2.3 months (range: 21 days to 26 months) for
patients receiving HALAVEN [see Clinical Studies (14.2)].
The most common adverse reactions (≥25%) reported in patients receiving HALAVEN were
Howfatigue,
willnausea,
I receive
HALAVEN?
alopecia,
constipation, peripheral neuropathy, abdominal pain, and pyrexia. The
most common (≥5%) Grade 3-4 laboratory abnormalities reported in patients receiving HALAVEN
• HALAVEN
is given
by intravenous
(IV) injection
your serious
vein. adverse reactions
were neutropenia,
hypokalemia,
and hypocalcemia.
The most in
common
reported in patients
receiving
HALAVENof
were
neutropeniawith
(4.9%)each
and pyrexia
Permanent
• HALAVEN
is given
in “cycles”
treatment,
cycle(4.5%).
lasting
discontinuation
of HALAVEN for adverse reactions occurred in 8% of patients. The most common
21
days.
adverse reactions resulting in discontinuation of HALAVEN were fatigue and thrombocytopenia
• HALAVEN
is usuallypercent
givenofon
day 1required
and day
8 ofone
a dose
treatment
cycle.
(0.9% each). Twenty-six
patients
at least
reduction.
The most
frequent adverse reactions that led to dose reduction were neutropenia (18%) and peripheral
What
are the(4.0%).
possible side effects of HALAVEN?
neuropathy
Table 3 summarizes the incidence of adverse reactions occurring in at least 10% of patients in
the HALAVEN-treated
in Studyside
2. effects, including:
HALAVEN
may causearm
serious
Table 3: Adverse Reactionsa Occurring in ≥10% (all Grades) of Patients Treated on
• See “What
is thearm
most
important
information
should
knowArm
the HALAVEN
and at
a Higher Incidence
than inIthe
Dacarbazine
(Between
Arm Difference of ≥5% for All Grades or ≥2% for Grades 3 and 4)
about
HALAVEN?”
(Study 2)b
• HALAVEN
can cause changes in your heartbeat (called QT
HALAVEN
prolongation).
heartbeats. YourDacarbazine
healthcare
Adverse
Reaction This can cause irregular
n=223
n=221
provider may do heart monitoring
(electrocardiogram
ECG) or Grades
blood 3-4
All Grades
Grades 3-4 AllorGrades
Nervous
tests system
during disorders
your treatment with HALAVEN to check for
Peripheral
Neuropathyc
29%
3.1%
8%
0.5%
heart problems.
Headache
18%
0%
10%
General
The
mostdisorders
common side effects of HALAVEN in people with breast
Pyrexia
28%
0.9%
14%
cancer
include: disorders Gastrointestinal
32%
•Constipation
low white blood cell count (neutropenia)
Abdominal paind
29%
•Stomatitis
low red blood cell count (anemia)
14%
Skin
and subcutaneous
tissue disorders •
weakness
or tiredness
Alopecia
35%
0%
0.5%
0.9%•
1.8%
0.9%•
NAe
26%(alopecia)
0.5%
hair loss
23%
4.1%
nausea5%
0.5%
• constipation
e
2.7%
Infections The
most common side effects of HALAVEN in people with
Urinary tract include:
infection
11%
2.2%
5%
liposarcoma
a
NA
0.5%
Adverse reactions were graded per National Cancer Institute Criteria for Adverse Events
• constipation
•version
tiredness
4.03 (NCI CTCAE v4.03).
b
Safety data from one study site enrolling six patients were excluded.
• stomach pain
•
c nausea
Includes peripheral neuropathy, peripheral sensorimotor neuropathy, peripheral motor
• paraesthesia.
fever
•neuropathy,
hair losspolyneuropathy,
(alopecia) peripheral sensory neuropathy, and
d
Includes abdominal pain, upper abdominal pain, lower abdominal pain, abdominal discomfort.
e
Your
provider
will
donot
blood
tests
before
and during treatment
Nothealthcare
applicable; (grading
system
does
specify
> Grade
2 for alopecia).
while
youclinically
are taking
HALAVEN.
The most
common
to blood tests
Other
important
adverse reactions
occurring
in ≥10%changes
of the HALAVEN-treated
patientswith
were:liposarcoma include:
in people
• Gastrointestinal Disorders: nausea (41%); vomiting (19%), diarrhea (17%)
• low
whiteDisorders:
blood cellasthenia/fatigue
count (neutropenia)
• General
(62%); peripheral edema (12%)
• Metabolism
and levels
Nutrition
appetite (19%)
• decreased
blood
ofDisorders:
potassiumdecreased
or calcium
• Musculoskeletal and Connective Tissue Disorders: arthralgia/myalgia (16%);
Tell your
healthcare
back
pain (16%) provider about any side effect that bothers you or that
Respiratory
does•not
go away.Disorders: cough (18%)
Less Common Adverse Reactions: The following additional clinically important adverse reactions
were reported in ≥5% to <10% of the HALAVEN-treated group:
These
are not all the possible side effects of HALAVEN. Call your doctor
• Blood and Lymphatic System Disorders: thrombocytopenia
for medical
advice about
side
effects. You may report side effects to FDA
• Eye Disorders:
increased
lacrimation
at 1-800-FDA-1088.
• Gastrointestinal Disorders: dyspepsia
• Metabolism and Nutrition Disorders: hyperglycemia
General
informationand
about
HALAVEN
• Musculoskeletal
Connective
Tissue Disorders:
muscle spasms,
musculoskeletal pain
Medicines
are System
sometimes
prescribed
for purposes
• Nervous
Disorders:
dizziness,
dysgeusia other than those listed in a
• Psychiatric
Disorders:
insomnia,
anxiety
Patient
Information
leaflet. You
can ask
your pharmacist or healthcare provider
• Respiratory,
Thoracic,
and Mediastinal
Disorders:
oropharyngeal
pain
for information
about
HALAVEN
that is written
for health
professionals.
• Vascular Disorders: hypotension
What are the ingredients in HALAVEN?
© 2016 Eisai Inc. All rights reserved. HALA-US0277(1)
Printed in USA / October 2016
✁
✃
Table 4: Laboratory Abnormalities Occurring in ≥10% (all Grades) of Patients Treated
on the HALAVEN arm and at a Higher Incidence than in the Dacarbazine Arm
Active Ingredient:
mesylate
(Between Armeribulin
Difference
of ≥5% for All Grades or ≥2% for Grades 3 and 4)a
(Study 2)†
Inactive
Dacarbazine
LaboratoryIngredients:
Abnormality ethanol, water Halaven
All Grades Grades 3-4 All Grades Grades 3-4
®
is a registered trademark used by Eisai Inc. under license from
HALAVEN
Hematology
70%
4.1%
52%
6%
EisaiAnemia
R&D Management Co., Ltd.
Neutropenia
63%
32%
30%
8.9%
Chemistry by:
Distributed
43%
2.3%
28%
2.3%
EisaiIncreased
Inc. alanine aminotransferase
(ALT)
Woodcliff
Lake,
NJ 07677
Increased
aspartate
36%
0.9%
16%
0.5%
aminotransferase (AST)
For more
information,
go
to
www.HALAVEN.com
or
call
Eisai
Inc.
Hypokalemia
30%
5.4%
14%
2.8%
Hypocalcemia
18%
1.4%
at 1-877-873-4724.
If you would like a28%
leaflet with5%
larger printing,
Hypophosphatemia
20%
3.2%
11%
1.4%
please
contact
Eisai
Inc.
at
1-877-873-4724.
a
Each test incidence is based on the number of patients who had both baseline and at least one
on-study measurement and at least 1 grade increase from baseline. Halaven group (range
This221-222)
Patientand
Information
has been
dacarbazine group
(range approved
214-215) by the
†
results
graded per NCI CTCAE
v4.03. 01/2016
U.S.Laboratory
Food and
Drugwere
Administration.
Revised:
6.2 Postmarketing Experience
PATIENT
INFORMATION
The following adverse drug reactions
have been
identified during post-approval of HALAVEN.
®
Because these reactions are reported
voluntarily
from a population of uncertain size, it is not always
HALAVEN
(HAL-ih-ven)
possible to reliably estimate their frequency
or establish
a causal relationship to drug exposure.
(eribulin
mesylate)
• Blood and Lymphatic System Disorders: lymphopenia
injection,
for
intravenous
use
• Gastrointestinal Disorders: pancreatitis
• Hepatobiliary
Disorders:
hepatotoxicity
What
is the most
important
information I should know about HALAVEN?
• Immune System Disorders: drug hypersensitivity
HALAVEN
can
cause
serious
side effects,
including:
• Infections and Infestations: pneumonia,
sepsis/neutropenic
sepsis
• Metabolism and Nutrition Disorders: hypomagnesemia, dehydration
Low white
bloodand
cell
count (neutropenia).
Thislung
candisease
lead to
•• Respiratory,
thoracic
mediastinal
disorders: interstitial
• Skin
and Subcutaneous
Tissue
Disorders:
pruritus, Your
Stevens-Johnson
syndrome,
serious
infections that
could
lead to death.
healthcare
provider
toxic
necrolysis
willepidermal
check your
blood cell counts before you receive each dose of
7 DRUG INTERACTIONS
and Drugs
duringontreatment.
7.1 HALAVEN
Effects of Other
HALAVEN Call your healthcare provider right
away if interactions
you develop
any of with
these
symptoms
infection:
No drug-drug
are expected
CYP3A4
inhibitors,ofCYP3A4
inducers or
P-glycoprotein
(P-gp)(temperature
inhibitors. Clinically
meaningful
differences in exposure (AUC) were not
– fever
above
100.5°F)
observed in patients with advanced solid tumors when HALAVEN was administered with or
– chills (a strong inhibitor of CYP3A4 and a P-gp inhibitor) and when HALAVEN
without ketoconazole
was administered
– coughwith or without rifampin (a CYP3A4 inducer) [see Clinical Pharmacology (12.3)].
7.2 Effect of HALAVEN on Other Drugs
– burning
pain when
urinate
Eribulin does
not inhibitorCYP1A2,
CYP2C9,you
CYP2C19,
CYP2D6, CYP2E1 or CYP3A4 enzymes
or induce CYP1A2, CYP2C9, CYP2C19 or CYP3A4 enzymes at relevant clinical concentrations.
•
Numbness,
tingling,
or
pain
in
your
hands
feet
(peripheral
Eribulin is not expected to alter the plasma concentrations
of drugsor
that
are substrates
of these
neuropathy).
Peripheral(12.3)].
neuropathy is common with HALAVEN and
enzymes
[see Clinical Pharmacology
8 USEsometimes
IN SPECIFICcan
POPULATIONS
be severe. Tell your healthcare provider if you have
8.1 Pregnancy
new
or
worsening
symptoms of peripheral neuropathy.
Risk Summary
• Your
healthcare
may delay,
your dose,
or stop
Based
on findings
from anprovider
animal reproduction
studydecrease
and its mechanism
of action,
HALAVEN
can treatment
cause fetal harm
when
administered
to a pregnant
woman
[see Clinical Pharmacology
with
HALAVEN
if you
have side
effects.
(12.1)]. There are no available data on the use of HALAVEN during pregnancy. In an animal
reproduction
mesylate
caused
embryo-fetal
toxicity when administered
See
“Whatstudy,
areeribulin
possible
side
effects
of HALAVEN?”
for more to
pregnant rats during organogenesis at doses below the recommended human dose [see Data].
information
about
side
effects.
Advise pregnant women of the potential risk to a fetus.
The estimated
background risks of major birth defects and miscarriage for the indicated populations
What
is HALAVEN?
are unknown. In the U.S. general population, the estimated background risk of major birth defects
and miscarriage in clinically-recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
HALAVEN
is a prescription medicine used to treat people with:
Data
Animal
Data
• Breast cancer
In an embryo-fetal developmental toxicity study, pregnant rats received intravenous infusion of
– that during
has spread
to other
partsDays
of the
and
eribulin mesylate
organogenesis
(Gestation
8, 10,body,
and 12)
at doses approximately
0.04, 0.13,
andhave
0.64 times
the recommended
human dose,
based
on body surface
area.
– 0.43
who
already
received certain
types
of anticancer
medicines
Increased abortion and severe fetal external or soft tissue malformations, including the
cancer
has
spreadand spleen, were observed at doses 0.64
absence of aafter
lowerthe
jaw and
tongue,
or stomach
times
the recommended human dose of 1.4 mg/m2 based on body surface area. Increased
• Liposarcoma
embryo-fetal death/resorption, reduced fetal weights, and minor skeletal anomalies consistent
– that cannot
be treated
with
surgery
hasa spread
other
with developmental
delay were
also reported
at doses
at oror
above
maternallytotoxic
doseparts
of
of0.43
thetimes
body,theand
approximately
recommended human dose.
8.2 Lactation
– who have received treatment with a certain type of
Risk Summary
anticancer medicine
There is no information regarding the presence of eribulin mesylate or its metabolites in human
the effects on the breastfed infant, or the effects on milk production. No lactation studies
Itmilk,
not
known
if HALAVEN
isofsafe
and effective
children
under
18 years
inisanimals
were conducted.
Because
the potential
for seriousinadverse
reactions
in breastfed
ofinfants
age.from eribulin mesylate, advise women not to breastfeed during treatment with HALAVEN
and for 2 weeks after the final dose.
Before
you and
receive
tell
your healthcare provider about
8.3 Females
Males HALAVEN,
of Reproductive
Potential
Contraception
all
of your medical conditions, including if you:
Females
• have
liver orfrom
kidney
problems
Based
on findings
an animal
reproduction study and its mechanism of action, HALAVEN
can
cause fetal
when administered
to aa pregnant
[see
Use in Specific
• have
heartharm
problems,
including
problemwoman
called
congenital
long
Populations (8.1)]. Advise females of reproductive potential to use effective contraception
QT
syndrome
during treatment with HALAVEN and for at least 2 weeks following the final dose.
Males
• have low potassium or low magnesium in your blood
Based
its mechanism
action,toadvise
males with
female partners
of reproductive
potential
to use
• areonpregnant
orofplan
become
pregnant.
HALAVEN
can harm
your
effective contraception during treatment with HALAVEN and for 3.5 months following the final dose.
unborn baby. Tell your healthcare provider right away if you become
Infertility
pregnant or think you are pregnant during treatment with HALAVEN.
Males
Based on–animal
data, HALAVEN
mayable
resulttoin become
damage to pregnant
male reproductive
tissues
Females
who are
should
useleading
an to
impaired fertility of unknown duration [see Nonclinical Toxicology (13.1)].
effective
birth
control
during
treatment
with
HALAVEN
and
for at
8.4 Pediatric Use
least
2 weeksofafter
theinfinal
dose
of HALAVEN.
The safety and
effectiveness
HALAVEN
pediatric
patients
below the age of 18 years have
not been–established.
Males should use an effective form of birth control when
8.5 Geriatric Use
having
with numbers
femaleofpartners
who
are able
to become
Study 1 did not
includesex
sufficient
subjects with
metastatic
breast
cancer aged 65
pregnant
during
treatment
withdifferently
HALAVEN
and forsubjects.
3 1/2 Of
months
years and older
to determine
whether
they respond
from younger
the
827 subjects(14
whoweeks)
received after
the recommended
dose and
of HALAVEN in clinical studies
the final dose
of schedule
HALAVEN.
with advanced breast cancer, 15% (121/827) were 65 and older, and 2% (17/827) patients
• are
breastfeeding
ordifferences
plan to breastfeed.
It is notbetween
knownthese
if HALAVEN
were
75 and
older. No overall
in safety were observed
subjects
into your breast milk. Do not breastfeed during treatment with
andpasses
younger subjects.
Clinical
studies ofand
HALAVEN
not include
in Study 2 aged 65
HALAVEN
for 2didweeks
aftera sufficient
the finalnumber
doseofofsubjects
HALAVEN.
years and older to determine whether they respond differently from younger subjects.
8.6 Hepatic
Impairment provider about all the medicines you take,
Tell
your healthcare
Administration
of HALAVENand
at a dose
of 1.1 mg/m2 to patients
with mildvitamins,
hepatic impairment
including
prescription
over-the-counter
medicines,
and
2
and 0.7 mg/m to patients with moderate hepatic impairment resulted in similar exposure to
2
herbal
eribulin supplements.
as a dose of 1.4 mg/m to patients with normal hepatic function. Therefore, a lower
starting dose of 1.1 mg/m2 is recommended for patients with mild hepatic impairment
(Child-Pugh A) and of 0.7 mg/m2 is recommended for patients with moderate hepatic
impairment (Child-Pugh B). HALAVEN was not studied in patients with severe hepatic
impairment (Child-Pugh C) [see Dosage and Administration (2.1), Clinical Pharmacology (12.3)].
8.7 Renal Impairment
For patients with moderate or severe renal impairment (CLcr 15-49 mL/min), reduce the starting
dose to 1.1 mg/m2 [see Dosage and Administration (2.1), Clinical Pharmacology (12.3)].
10 OVERDOSAGE
Overdosage of HALAVEN has been reported at approximately 4 times the recommended dose,
which resulted in Grade 3 neutropenia lasting seven days and a Grade 3 hypersensitivity reaction
lasting one day.
There is no known antidote for HALAVEN overdose.
11 DESCRIPTION
HALAVEN contains eribulin mesylate, a microtubule dynamics inhibitor. Eribulin mesylate is a
synthetic analogue of halichondrin B, a product isolated from the marine sponge Halichondria
okadai. The chemical name for eribulin mesylate is 11,15:18,21:24,28-Triepoxy-7,9-ethano12,15-methano-9H,15H-furo[3,2-i]furo[2',3':5,6]pyrano[4,3-b][1,4]dioxacyclopentacosin-5(4H)-one,
2-[(2S)-3-amino-2-hydroxypropyl]hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)-,
(2R,3R,3aS,7R,8aS,9S,10aR,11S,12R,13aR,13bS,15S,18S,21S,24S,26R,28R,29aS)-,
methanesulfonate (salt). It has a molecular weight of 826.0 (729.9 for free base). The empirical
formula is C40H59NO11•CH4O3S. Eribulin mesylate has the following structural formula:
H3C
O H
H
H2N
HO
H
H H O
O
H
H
H2C
O
H
H
CH2
O
H
H
H O O
O
CH3
H
H
O
H
H
O
H3C SO3H
H
H
HALAVEN is a clear, colorless, sterile solution for intravenous administration. Each vial contains
1 mg of eribulin mesylate as a 0.5 mg/mL solution in ethanol: water (5:95).
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
Eribulin inhibits the growth phase of microtubules without affecting the shortening phase and
sequesters tubulin into nonproductive aggregates. Eribulin exerts its effects via a tubulin-based
antimitotic mechanism leading to G2/M cell-cycle block, disruption of mitotic spindles, and,
ultimately, apoptotic cell death after prolonged mitotic blockage.
In addition, eribulin treatment of human breast cancer cells caused changes in morphology and
gene expression as well as decreased migration and invasiveness in vitro. In mouse xenograft
models of human breast cancer, eribulin treatment was associated with increased vascular
perfusion and permeability in the tumor cores, resulting in reduced tumor hypoxia, and changes
in the expression of genes in tumor specimens associated with a change in phenotype.
12.2 Pharmacodynamics
Cardiac Electrophysiology
The effect of HALAVEN on the QTc interval was assessed in an open-label, uncontrolled,
multicenter, single-arm dedicated QT trial. A total of 26 patients with solid tumors received
1.4 mg/m2 of HALAVEN on Days 1 and 8 of a 21-day cycle. A delayed QTc prolongation was
observed on Day 8, with no prolongation observed on Day 1. The maximum mean QTcF change
from baseline (95% upper confidence interval) was 11.4 (19.5) ms.
12.3 Pharmacokinetics
The pharmacokinetics (PK) of eribulin is linear with a mean elimination half-life of
approximately 40 hours, a mean volume of distribution of 43 L/m2 to 114 L/m2 and mean
clearance of 1.16 L/hr/m2 to 2.42 L/hr/m2 over the dose range of 0.25 mg/m2 to 4.0 mg/m2.
The human plasma protein binding of eribulin at concentrations of 100 ng/mL to 1,000 ng/mL
ranges from 49% to 65%. Eribulin exposure after multiple dosing is comparable to that following
a single dose. No accumulation of eribulin is observed with weekly administration.
Elimination
Metabolism
Unchanged eribulin was the major circulating species in plasma following administration of
14
C-eribulin to patients. Metabolite concentrations represented <0.6% of parent compound,
confirming that there are no major human metabolites of eribulin. Cytochrome P450 3A4
(CYP3A4) negligibly metabolizes eribulin in vitro.
Excretion
Eribulin is eliminated primarily in feces unchanged. After administration of 14C-eribulin to patients,
approximately 82% of the dose was eliminated in feces and 9% in urine. Unchanged eribulin
accounted for approximately 88% and 91% of total eribulin in feces and urine, respectively.
Specific Populations
Age, Sex, and Race/Ethnicity: Based on a population pharmacokinetic analysis with data
collected from 340 patients, sex, race, and age do not have a clinically meaningful effect on the
exposure of eribulin.
Hepatic Impairment
In a study evaluating the effect of hepatic impairment on the PK of eribulin, eribulin exposures
increased by 1.8-fold in patients with mild hepatic impairment (Child-Pugh A; n=7) and by 2.5-fold
in patients with moderate (Child-Pugh B; n=5) hepatic impairment as compared to patients with
normal hepatic function (n=6). Administration of HALAVEN at a dose of 1.1 mg/m2 to patients
with mild hepatic impairment and 0.7 mg/m2 to patients with moderate hepatic impairment
resulted in similar exposure to eribulin at a dose of 1.4 mg/m2 to patients with normal hepatic
function [see Dosage and Administration (2.1), Use in Specific Populations (8.6)].
Renal Impairment
In a study evaluating the effect of renal impairment on the PK of eribulin, patients with moderate
(CLcr 30-49 mL/min; n=7) and severe renal impairment (CLcr 15-29 mL/min; n=6) had 1.5-fold
higher eribulin dose-normalized exposures compared to that in patients with normal renal
function (CLcr ≥ 80 mL/min; n=6). There were no clinically meaningful changes in patients with
mild renal impairment (CLcr 50-79 mL/min; n=27) [see Dosage and Administration (2.1), Use in
Specific Populations (8.7)].
Drug Interaction Studies
Effect of Strong Inhibitors or Inducers of CYP3A4 on Eribulin: The effect of a strong CYP3A4
inhibitor and a P-gp inhibitor, ketoconazole, on the PK of eribulin was studied in a crossover trial
of 12 patients with advanced solid tumors. No clinically relevant PK interaction was observed
when HALAVEN was administered with or without ketoconazole (the geometric mean ratio of the
AUC: 0.97; 90% CI: 0.83, 1.12).
The effect of a CYP3A4 inducer, rifampin, on the PK of eribulin was studied in a crossover trial of
14 patients with advanced solid tumors. No clinically relevant PK interaction was observed when
HALAVEN was administered with or without rifampin (the geometric mean ratio of the AUC:
1.10; 90 CI%: 0.91, 1.34).
Effect of Eribulin on CYP Substrates: Eribulin shows no induction potential for CYP1A, CYP2B6,
CYP2C9, CYP2C19, and CYP3A in primary human hepatocytes. Eribulin inhibits CYP3A4 activity
in human liver microsomes, but it is unlikely that eribulin will substantially increase the plasma
levels of CYP3A4 substrates. No significant inhibition of CYP1A2, CYP2C9, CYP2C19, CYP2D6,
or CYP2E1 was detected with eribulin concentrations up to 5 μM in pooled human liver
microsomes. In vitro drug interaction studies indicate that eribulin does not inhibit drugs that are
substrates of these enzymes and it is unlikely that eribulin will affect plasma levels of drugs that
are substrates of CYP enzymes.
Effect of Transporters on Eribulin: In vitro data suggest that eribulin at clinically relevant
concentrations is a substrate of P-gp, but is not a substrate of breast cancer resistance protein
(BCRP), multidrug resistance proteins (MRP2, MRP4), bile salt extrusion pump (BSEP), organic
anion transporting polypeptides (OATP1B1, OATP1B3), organic anion transporters (OAT1, OAT3),
organic cation transporters (OCT1, OCT2), or multidrug and toxin extrusion 1 (MATE1).
Effect of Eribulin on Transporters: In vitro data suggest that eribulin at clinically relevant
concentrations may inhibit P-gp, but does not inhibit BCRP, OATP1B1, OCT1, OAT1, OAT3, or MATE1.
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
Carcinogenicity studies have not been conducted with eribulin mesylate. Eribulin mesylate was
not mutagenic in in vitro bacterial reverse mutation assays (Ames test). Eribulin mesylate was
positive in mouse lymphoma mutagenesis assays, and was clastogenic in an in vivo rat bone
marrow micronucleus assay.
Fertility studies have not been conducted with eribulin mesylate in humans or animals; however,
nonclinical findings in repeat-dose dog and rat toxicology studies suggest that male fertility
may be compromised by treatment with eribulin mesylate. Rats exhibited testicular toxicity
(hypocellularity of seminiferous epithelium with hypospermia/aspermia) following dosing with
eribulin mesylate at or above 0.43 times the recommended human dose (based on body surface
area) given once weekly for 3 weeks, or at or above 0.21 times the recommended human dose
(based on body surface area) given once weekly for 3 out of 5 weeks, repeated for 6 cycles.
Testicular toxicity was also observed in dogs given 0.64 times the recommended human dose
(based on body surface area) weekly for 3 out of 5 weeks, repeated for 6 cycles.
14 CLINICAL STUDIES
14.1 Metastatic Breast Cancer
Study 1 was an open-label, randomized, multicenter trial of 762 patients with metastatic breast
cancer who received at least two chemotherapeutic regimens for the treatment of metastatic
disease and experienced disease progression within 6 months of their last chemotherapeutic
regimen. Patients were required to receive prior anthracycline- and taxane-based chemotherapy
for adjuvant or metastatic disease. Patients were randomized (2:1) to receive HALAVEN (n=508)
or a single agent therapy selected prior to randomization (control arm, n=254). Randomization
was stratified by geographic region, HER2/neu status, and prior capecitabine exposure.
HALAVEN was administered at a dose of 1.4 mg/m2 on Days 1 and 8 of a 21-day cycle.
HALAVEN-treated patients received a median of 5 cycles (range: 1 to 23 cycles) of therapy.
Control arm therapy consisted of 97% chemotherapy (26% vinorelbine, 18% gemcitabine, 18%
capecitabine, 16% taxane, 9% anthracycline, 10% other chemotherapy), and 3% hormonal
therapy. The main efficacy outcome was overall survival.
Patient demographic and baseline characteristics were comparable between the treatment
arms. The median age was 55 (range: 27 to 85 years) and 92% were White. Sixty-four percent
of patients were enrolled in North America/Western Europe/Australia, 25% in Eastern Europe/
Russia, and 11% in Latin America/South Africa. Ninety-one percent of patients had a baseline
ECOG performance status of 0 or 1. Tumor prognostic characteristics, including estrogen receptor
status (positive: 67%, negative: 28%), progesterone receptor status (positive: 49%, negative:
39%), HER2/neu
receptor status (positive: 16%, negative: 74%), triple negative status (ER , PR ,
HER2/neu : 19%), presence of visceral disease (82%, including 60% liver and 38% lung) and bone
disease (61%), and number of sites of metastases (greater than two: 50%), were also similar in
the HALAVEN and control arms. Patients received a median of four prior chemotherapy regimens in
both arms.
In Study 1, a statistically significant improvement in overall survival was observed in patients
randomized to the HALAVEN arm compared to the control arm (see Table 5). An updated, unplanned
survival analysis, conducted when 77% of events had been observed (see Figure 1), was consistent
with the primary analysis. In patients randomized to HALAVEN, the objective response rate by the
RECIST criteria was 11% (95% CI: 8.6%, 14.3%) and the median response duration was 4.2 months
(95% CI: 3.8, 5.0 months).
Table 5: Comparison of Overall Survival in HALAVEN and Control Arm - Study 1
Overall Survival
HALAVEN
(n=508)
Control Arm
(n=254)
Primary survival analysis
Number of deaths
274
148
Median, months (95% CI)
13.1 (11.8, 14.3)
10.6 (9.3, 12.5)
a
Hazard Ratio (95% CI)
0.81 (0.66, 0.99)
P valueb
0.041
Updated survival analysis
Number of deaths
386
203
Median, months (95% CI)
13.2 (12.1, 14.4)
10.6 (9.2, 12.0)
CI = confidence interval
a
Based on Cox proportional hazards model stratified by geographic region, HER2 status, and
prior capecitabine therapy.
b
Based on a log-rank test stratified by geographic region, HER2 status, and prior capecitabine
therapy.
Figure 2: Kaplan-Meier Curves of Overall Survival in the Liposarcoma Stratum in Study 2
Figure 1: Updated Overall Survival Analysis for Study 1
1.0
1.0
HALAVEN
Dacarbazine
0.9
0.8
0.7
Survival Probability
Proportion of Patients Alive
0.8
HALAVEN (N=508)
0.6
0.5
0.4
0.6
0.4
0.2
0.3
0.0
0.2
0
CONTROL (N=254)
3
6
9
12
15
18
21
24
27
30
33
36
39
42
45
12
3
7
2
4
0
2
0
0
0
0
0
0
0
Survival Time (months)
0.1
Subjects at Risk:
HALAVEN
Dacarbazine
0.0
0
Number of 508
Patients at Risk 254
6
12
406
178
18
Time (months)
274
106
24
142
61
54
26
30
36
11
5
0
0
14.2 Liposarcoma
The efficacy and safety of HALAVEN were evaluated in Study 2, an open-label, randomized
(1:1), multicenter, active-controlled trial. Eligible patients were required to have unresectable,
locally advanced or metastatic liposarcoma or leiomyosarcoma, at least two prior systemic
chemotherapies (one of which must have included an anthracycline), and disease progression
within 6 months of the most recent chemotherapy regimen. Patients were randomized to
HALAVEN 1.4 mg/m2 administered intravenously on Days 1 and 8 of a 21-day cycle or to
dacarbazine at a dose of 850 mg/m2, 1000 mg/m2, or 1200 mg/m2 administered intravenously
every 21 days (dacarbazine dose was selected by the investigator prior to randomization).
Treatment continued until disease progression or unacceptable toxicity. Randomization was
stratified by histology (liposarcoma or leiomyosarcoma), number of prior therapies (2 vs. > 2),
and geographic region (U.S. and Canada vs. Western Europe, Australia, and Israel vs. Eastern
Europe, Latin America, and Asia). The major efficacy outcome measure was overall survival
(OS). Additional efficacy outcome measures were progression-free survival (PFS) and confirmed
objective response rate (ORR) as assessed by the investigator according to Response Evaluation
Criteria in Solid Tumors (RECIST v1.1). Patients in the dacarbazine arm were not offered
HALAVEN at the time of disease progression.
A total of 446 patients were randomized, 225 to the HALAVEN arm and 221 to the dacarbazine
arm. The median age was 56 years (range: 24 to 83); 33% were male; 73% were White; 44%
had ECOG performance status (PS) 0 and 53% had ECOG PS 1; 68% had leiomyosarcoma
and 32% had liposarcoma; 39% were enrolled in U.S. and Canada (Region 1) and 46% were
enrolled in Western Europe, Australia, and Israel (Region 2); and 47% received more than two
prior systemic chemotherapies. The most common (>40%) prior systemic chemotherapies were
doxorubicin (90%), ifosfamide (62%), gemcitabine (59%), trabectedin (50%), and docetaxel (48%).
Of the 143 patients with liposarcoma, the median age was 55 years (range: 32 to 83); 62%
were male, 72% were White; 41% had ECOG PS of 0 and 53% had ECOG PS of 1; 35% were
enrolled in Region 1 and 51% were enrolled in Region 2; and 44% received more than two prior
systemic chemotherapies. The distribution of subtypes of liposarcoma, based on local histologic
assessment, were 45% dedifferentiated, 37% myxoid/round cell, and 18% pleomorphic.
Study 2 demonstrated a statistically significant improvement in OS in patients randomized to
HALAVEN compared with dacarbazine (see Table 6). There was no significant difference in
progression-free survival in the overall population. Treatment effects of HALAVEN were limited
to patients with liposarcoma based on pre-planned, exploratory subgroup analyses of OS and
PFS (see Tables 6 and 7 and Figure 2). There was no evidence of efficacy of HALAVEN in patients
with advanced or metastatic leiomyosarcoma in Study 2 (see Table 7).
Table 6: Efficacy Results for the Liposarcoma Stratum and All Patients* in Study 2a
Overall Survival
Deaths, n (%)
Median, months (95% CI)
Liposarcoma
Stratum
Halaven
Dacarbazine
(n=71)
(n=72)
52 (73)
63 (88)
15.6
8.4
(10.2, 18.6)
(5.2, 10.1)
0.51 (0.35, 0.75)
N/A†
All Patients*
Halaven
(n=225)
Dacarbazine
(n=221)
173 (77)
179 (81)
13.5
11.3
(11.1, 16.5)
(9.5, 12.6)
0.75 (0.61, 0.94)
0.011
Hazard ratio (HR) (95% CI)
Stratified log-rank p value
Progression-free survival
Events, n (%)
57 (80)
59 (82)
194 (86)
185 (84)
Disease progression
53
52
180
170
Death
4
7
14
15
Median, months (95% CI)
2.9 (2.6, 4.8) 1.7 (1.4, 2.6) 2.6 (2.0, 2.8) 2.6 (1.7, 2.7)
HR (95% CI)
0.52 (0.35, 0.78)
0.86 (0.69, 1.06)
Objective response rate
Objective response rate
1.4 (0, 7.6)
0 (0, 4.2)
4.0 (1.8, 7.5) 5.0 (2.5, 8.7)
(%) (95% CI)
a
Efficacy data from one study site enrolling six patients were excluded.
* All patients = liposarcoma and leiomyosarcoma.
†
N/A = not applicable
71
72
63
59
51
42
43
33
39
22
34
17
30
12
20
11
15
6
Table 7: Efficacy Results for the Leiomyosarcoma Stratum in Study 2a
Leiomyosarcoma Stratum
Halaven (n=154)
Dacarbazine (n=149)
Overall survival
Deaths, n (%)
121 (79)
116 (78)
Median, months (95% CI)
12.8 (10.3, 14.8)
12.3 (11.0, 15.1)
HR (95% CI)
0.90 (0.69, 1.18)
Progression-free survival
Events, n (%)
137 (89)
126 (85)
Disease progression
127
118
Death
10
8
Median, months (95% CI)
2.2 (1.5, 2.7)
2.6 (2.2, 2.9)
HR (95% CI)
1.05 (0.81, 1.35)
Objective response rate (%) (95% CI)
5.2 (2.3, 10)
7.4 (3.7, 12.8)
a
Efficacy data from one study site enrolling six patients were excluded.
16 HOW SUPPLIED/STORAGE AND HANDLING
NDC 62856-389-01
Injection: 1 mg/2 mL, in a single-use vial. One vial per carton.
Store at 25°C (77°F); excursions permitted to 15° – 30° C (59° – 86° F). Do not freeze. Store the
vials in their original cartons.
17 PATIENT COUNSELING INFORMATION
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Neutropenia
Advise patients to contact their health care provider for a fever of 100.5°F or greater or other
signs or symptoms of infection such as chills, cough, or burning or pain on urination [see
Warnings and Precautions (5.1)].
Peripheral Neuropathy
Advise patients to inform their healthcare providers of new or worsening numbness, tingling and
pain in their extremities [see Warnings and Precautions (5.2)].
Embryo-Fetal Toxicity
• Advise females of reproductive potential of the potential risk to a fetus and to inform their
healthcare provider of a known or suspected pregnancy [see Warnings and Precautions
(5.3), Use in Specific Populations (8.1)].
• Advise females of reproductive potential to use effective contraception during treatment
with HALAVEN and for at least 2 weeks after the final dose [see Use in Specific
Populations (8.3)].
• Advise males with female partners of reproductive potential to use effective contraception
during treatment with HALAVEN and for 3.5 months following the final dose [see Use in
Specific Populations (8.3)].
Lactation
Advise women not to breastfeed during treatment with HALAVEN and for 2 weeks after the final
dose [see Use in Specific Populations (8.2)].
Distributed by:
Eisai Inc.
Woodcliff Lake, NJ 07677
HALAVEN® is a registered trademark used by Eisai Inc. under license from
Eisai R&D Management Co., Ltd.
© 2016 Eisai Inc. All rights reserved. HALA-US0277(1)
Printed in USA / October 2016
✃
PATIENT INFORMATION
HALAVEN® (HAL-ih-ven)
(eribulin mesylate)
injection, for intravenous use
What is the most important information I should know about HALAVEN?
HALAVEN can cause serious side effects, including:
• Low white blood cell count (neutropenia). This can lead to
serious infections that could lead to death. Your healthcare provider
will check your blood cell counts before you receive each dose of
HALAVEN and during treatment. Call your healthcare provider right
away if you develop any of these symptoms of infection:
– fever (temperature above 100.5°F)
– chills
– cough
– burning or pain when you urinate
• Numbness, tingling, or pain in your hands or feet (peripheral
neuropathy). Peripheral neuropathy is common with HALAVEN and
sometimes can be severe. Tell your healthcare provider if you have
new or worsening symptoms of peripheral neuropathy.
• Your healthcare provider may delay, decrease your dose, or stop
treatment with HALAVEN if you have side effects.
See “What are possible side effects of HALAVEN?” for more
information about side effects.
What is HALAVEN?
HALAVEN is a prescription medicine used to treat people with:
• Breast cancer
– that has spread to other parts of the body, and
– who have already received certain types of anticancer medicines
after the cancer has spread
• Liposarcoma
– that cannot be treated with surgery or has spread to other parts
of the body, and
– who have received treatment with a certain type of
anticancer medicine
It is not known if HALAVEN is safe and effective in children under 18 years
of age.
Before you receive HALAVEN, tell your healthcare provider about
all of your medical conditions, including if you:
• have liver or kidney problems
• have heart problems, including a problem called congenital long
QT syndrome
• have low potassium or low magnesium in your blood
• are pregnant or plan to become pregnant. HALAVEN can harm your
unborn baby. Tell your healthcare provider right away if you become
pregnant or think you are pregnant during treatment with HALAVEN.
– Females who are able to become pregnant should use an
effective birth control during treatment with HALAVEN and for at
least 2 weeks after the final dose of HALAVEN.
– Males should use an effective form of birth control when
having sex with female partners who are able to become
pregnant during treatment with HALAVEN and for 3 1/2 months
(14 weeks) after the final dose of HALAVEN.
• are breastfeeding or plan to breastfeed. It is not known if HALAVEN
passes into your breast milk. Do not breastfeed during treatment with
HALAVEN and for 2 weeks after the final dose of HALAVEN.
Tell your healthcare provider about all the medicines you take,
including prescription and over-the-counter medicines, vitamins, and
herbal supplements.
How will I receive HALAVEN?
• HALAVEN is given by intravenous (IV) injection in your vein.
• HALAVEN is given in “cycles” of treatment, with each cycle lasting
21 days.
• HALAVEN is usually given on day 1 and day 8 of a treatment cycle.
What are the possible side effects of HALAVEN?
HALAVEN may cause serious side effects, including:
• See “What is the most important information I should know
about HALAVEN?”
• HALAVEN can cause changes in your heartbeat (called QT
prolongation). This can cause irregular heartbeats. Your healthcare
provider may do heart monitoring (electrocardiogram or ECG) or blood
tests during your treatment with HALAVEN to check for
heart problems.
The most common side effects of HALAVEN in people with breast
cancer include:
• low white blood cell count (neutropenia)
• low red blood cell count (anemia)
• weakness or tiredness
• hair loss (alopecia)
• nausea
• constipation
The most common side effects of HALAVEN in people with
liposarcoma include:
• tiredness
• nausea
• hair loss (alopecia)
• constipation
• stomach pain
• fever
Your healthcare provider will do blood tests before and during treatment
while you are taking HALAVEN. The most common changes to blood tests
in people with liposarcoma include:
• low white blood cell count (neutropenia)
• decreased blood levels of potassium or calcium
Tell your healthcare provider about any side effect that bothers you or that
does not go away.
These are not all the possible side effects of HALAVEN. Call your doctor
for medical advice about side effects. You may report side effects to FDA
at 1-800-FDA-1088.
General information about HALAVEN
Medicines are sometimes prescribed for purposes other than those listed in a
Patient Information leaflet. You can ask your pharmacist or healthcare provider
for information about HALAVEN that is written for health professionals.
What are the ingredients in HALAVEN?
Active Ingredient: eribulin mesylate
Inactive Ingredients: ethanol, water
HALAVEN® is a registered trademark used by Eisai Inc. under license from
Eisai R&D Management Co., Ltd.
Distributed by:
Eisai Inc.
Woodcliff Lake, NJ 07677
For more information, go to www.HALAVEN.com or call Eisai Inc.
at 1-877-873-4724. If you would like a leaflet with larger printing,
please contact Eisai Inc. at 1-877-873-4724.
This Patient Information has been approved by the
U.S. Food and Drug Administration. Revised: 01/2016
© 2016 Eisai Inc. All rights reserved. HALA-US0277(1)
Printed in USA / October 2016